<html><body> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5525">international conference</a></span> on harmonisation of technical requirements for registration of pharmaceuticals for human 
use   ich harmonised tripartite <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span>  bracketing and matrixing designs for stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> of new drug substances and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> q1d   current step 4 version dated 7 february 2002      this <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> has been developed by the appropriate ich expert <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4543">working</a></span> group and has been subject to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5532">consultation</a></span> by the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3099">regulatory</a></span> parties, in accordance with the ich process.  at step 4 of the process the final draft is <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2926">recommended</a></span> for adoption to the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3099">regulatory</a></span> bodies of the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/665"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/909"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4054"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4060">european</a></span></a></span></a></span> union</a></span>, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1524">japan</a></span> and usa.    q1d <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/486"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/494">document</a></span></a></span> history  first codification history date new codification november 2005 q1d <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1252">approval</a></span> by the steering committee under step 2 and release for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2859">public</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5532">consultation</a></span>. 10 november 2000 q1d current step 4 version q1d <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1252">approval</a></span> by the steering committee under step 4 and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2926">recommendation</a></span> for adoption to the three ich <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3099">regulatory</a></span> bodies. 7 february 2002 q1d       2  bracketing and matrixing designs for stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> of new drug substances and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> ich harmonised tripartite guidelines having reached step 4 of the ich steering committee meeting  on 7 february 2002, this <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> is <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2926">recommended</a></span> for adoption to the three <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3099">regulatory</a></span> parties to ich   table of contents     1. introduction...................................................................................................1 1.1 objectives of the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span>...............................................................................1 1.2 background........................................................................................................1 1.3 scope of the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span>.......................................................................................1 2. guidelines..........................................................................................................1 2.1 general...............................................................................................................1 2.2 applicability of reduced designs.....................................................................1 2.3 bracketing..........................................................................................................2 2.4 matrixing...........................................................................................................3 2.5 data evaluation................................................................................................7       bracketing and matrixing designs for stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> of new drug substances and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span>  1. introduction 1.1 objectives of the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> this <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> is intended to address recommendations on the application of bracketing and matrixing to stability studies conducted in accordance with principles outlined in the ich q1a(r) harmonised tripartite <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> on stability 
<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> of new drug substances and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> (hereafter referred to as the parent <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span>). 1.2 background the parent <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> notes that the use of matrixing and bracketing can be applied, if justified, to the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> of new drug substances and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span>, but provides no 
further <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guidance</a></span> on the subject.  1.3 scope of the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> this <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/486"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/494">document</a></span></a></span> provides <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guidance</a></span> on bracketing and matrixing study designs. specific principles are defined in this <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> for situations in which bracketing or matrixing can be applied. <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/623">sample</a></span> designs are provided for illustrative purposes, and 
should not be considered the only, or the most appropriate, designs in all cases. 2. guidelines 2.1 general a full study design is one in which <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/623">samples</a></span> for every combination of all design 
factors are <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tested</a></span> at all time points. a reduced design is one in which <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/623">samples</a></span> for every factor combination are not all <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tested</a></span> at all time points. a reduced design can be a suitable <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4328">alternative</a></span> to a full design when multiple design factors are involved. 
any reduced design should have the ability to adequately predict the retest period or 
shelf life. before a reduced design is considered, certain assumptions should be 
<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/184">assessed</a></span> and justified. the potential risk should be considered of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/871">establishing</a></span> a shorter retest period or shelf life than could be derived from a full design due to the reduced amount of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6030">data collected</a></span>. during the course of a reduced design study, a change to full <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> or to a less reduced design can be considered if a justification is provided and the principles of full designs and reduced designs are followed. however, proper adjustments should be made to the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4256">statistical</a></span> analysis, where applicable, to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/54"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/60"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/61">account</a></span></a></span></a></span> for the increase in 
<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/623">sample</a></span> size as a result of the change. once the design is changed, full <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> or less 
reduced <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> should be carried out through the remaining time points of the stability study. 2.2 applicability of reduced designs  reduced designs can be applied to the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">formal</a></span> stability study of most types of drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span>, although additional justification should be provided for certain complex 
drug delivery systems where there are a large number of potential drug-device <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6908">interactions</a></span>.  for the study of drug substances, matrixing is of limited utility and bracketing is generally not applicable. 1 bracketing and matrixing designs for stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span>  2 whether bracketing or matrixing can be applied <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5390">depends</a></span> on the circumstances, as discussed in detail below. the use of any reduced design should be justified. in 
certain cases, the condition described in this <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> is sufficient justification for 
use, while in other cases, additional justification should be provided. the type and 
level of justification in each of these cases will <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5390">depend</a></span> on the available supporting 
data. data variability and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> stability, as shown by supporting data, should be 
considered when a matrixing design is applied. bracketing and matrixing are reduced designs based on different principles. 
therefore, careful consideration and scientific justification should precede the use of bracketing and matrixing together in one design. 2.3 bracketing as defined in the glossary to the parent <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span>, bracketing is the design of a stability schedule such that only <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/623">samples</a></span> on the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5634">extremes</a></span> of certain design factors 
(e.g., strength, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> size and/or fill) are <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tested</a></span> at all time points as in a full design. the design assumes that the stability of any intermediate levels is 
represented by the stability of the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5634">extremes</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tested</a></span>.  the use of a bracketing design would not be considered appropriate if it cannot be 
demonstrated that the strengths or <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> sizes and/or fills selected for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> 
are indeed the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5634">extremes</a></span>. 2.3.1 design factors  design factors are variables (e.g., strength, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> size and/or fill) to be evaluated in a study design for their effect on <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> stability. 2.3.1.1 strength bracketing can be applied to studies with multiple strengths of identical or closely related formulations. examples include but are not limited to (1) capsules of 
different strengths made with different fill plug sizes from the same powder blend, (2) tablets of different strengths manufactured by compressing varying amounts of the same granulation, and (3) oral solutions of different strengths with formulations that differ only in minor excipients (e.g., colourants, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2658">flavourings</a></span>). with justification, bracketing can be applied to studies with multiple strengths where the relative amounts of drug substance and excipients change in a formulation. such justification can include a demonstration of comparable stability 
profiles among the different strengths of clinical or development batches.  in cases where different excipients are used among strengths, bracketing generally should not be applied.  2.3.1.2 <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> closure sizes and/or fills bracketing can be applied to studies of the same <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> closure system where either <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> size or fill varies while the other remains constant. however, if a bracketing design is considered where both <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> size and fill vary, it should not be assumed that the largest and smallest <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">containers</a></span> represent the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5634">extremes</a></span> of all 
<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/720">packaging</a></span> configurations. care should be taken to select the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5634">extremes</a></span> by comparing the various characteristics of the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> closure system that may affect <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> stability. these characteristics include <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> wall thickness, closure geometry, surface area to volume <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2902">ratio</a></span>, headspace to volume <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2902">ratio</a></span>, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/597">water</a></span> vapour permeation 
rate or <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2214">oxygen</a></span> permeation rate per dosage unit or unit fill volume, as appropriate.  bracketing and matrixing designs for stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span>  with justification, bracketing can be applied to studies for the same <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> when the closure varies. justification could include a discussion of the relative permeation rates of the bracketed <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> closure systems. 2.3.2 design considerations and potential risks if, after starting the studies, one of the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5634">extremes</a></span> is no longer expected to be <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/13"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1786">marketed</a></span></a></span>, the study design can be maintained to support the bracketed 
intermediates.  a commitment should be provided to carry out stability studies on the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/13"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1786">marketed</a></span></a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5634">extremes</a></span> post-<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1252">approval</a></span>. before a bracketing design is applied, its effect on the retest period or shelf life estimation should be <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/184">assessed</a></span>.  if the stability of the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5634">extremes</a></span> is shown to be 
different, the intermediates should be considered no more stable than the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4598">least</a></span> 
stable <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5634">extreme</a></span> (i.e., the shelf life for the intermediates should not exceed that for the 
<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4598">least</a></span> stable <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5634">extreme</a></span>). 2.3.3 design example an example of a bracketing design is given in table 1.  this example is based on a 
<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> available in three strengths and three <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> sizes.  in this example, it should be demonstrated that the 15 ml and 500 ml high-density polyethylene 
<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> sizes truly represent the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5634">extremes</a></span>. the batches for each selected combination should be <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tested</a></span> at each time point as in a full design.  table 1:     example of a bracketing design strength 50 mg 75 mg 100 mg batch 1 2 3 1 2 3 1 2 3 15 ml  t t t    t t t 100 ml           <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> size 500 ml  t t t    t t t key: t = <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/623">sample</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tested</a></span> 2.4 matrixing as defined in the glossary of the parent <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span>, matrixing is the design of a stability schedule such that a selected subset of the total number of possible <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/623">samples</a></span> for all factor combinations would be <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tested</a></span> at a specified time point. at a subsequent time point, another subset of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/623">samples</a></span> for all factor combinations would be <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tested</a></span>. the design assumes that the stability of each subset of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/623">samples</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tested</a></span> represents 
the stability of all <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/623">samples</a></span> at a given time point. the differences in the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/623">samples</a></span> for 
the same drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> should be identified as, for example, covering different 
batches, different strengths, different sizes of the same <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> closure system, 
and possibly, in some cases, different <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> closure systems. when a secondary <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/720">packaging</a></span> system contributes to the stability of the drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span>, 
matrixing can be performed across the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/720">packaging</a></span> systems. each <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition should be treated separately under its own matrixing design. matrixing should not be performed across <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> attributes. however, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4328">alternative</a></span> 
matrixing designs for different <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> attributes can be applied if justified.  3 bracketing and matrixing designs for stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span>  4 2.4.1 design factors matrixing designs can be applied to strengths with identical or closely related formulations. examples include but are not limited to (1) capsules of different strengths made with different fill plug sizes from the same powder blend, (2) tablets of different strengths manufactured by compressing varying amounts of the same granulation, and (3) oral solutions of different strengths with formulations that 
differ only in minor excipients (e.g., colourants or <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2658">flavourings</a></span>). other examples of design factors that can be matrixed include batches made by using the same process and equipment, and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> sizes and/or fills in the same 
<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> closure system. with justification, matrixing designs can be applied, for example, to different strengths where the relative amounts of drug substance and excipients change or where different excipients are used or to different <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> closure systems. 
justification should generally be based on supporting data.  for example, to matrix across two different closures or <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> closure systems, supporting data could be <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2292">supplied</a></span> showing relative moisture vapour transmission rates or similar <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2844">protection</a></span> against <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/626">light</a></span>. alternatively, supporting data could be <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2292">supplied</a></span> to show that the drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> is not affected by <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2214">oxygen</a></span>, moisture, or <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/626">light</a></span>. 2.4.2 design considerations a matrixing design should be balanced as far as possible so that each combination of factors is <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tested</a></span> to the same extent over the intended duration of the study and 
through the last time point prior to submission. however, due to the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2926">recommended</a></span> full <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> at certain time points, as discussed below, it may be difficult to achieve a complete balance in a design where time points are matrixed.  in a design where time points are matrixed, all selected factor combinations should 
be <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tested</a></span> at the initial and final time points, while only certain fractions of the 
designated combinations should be <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tested</a></span> at each intermediate time point. if full 
long-term data for the proposed shelf life will not be available for review before 
<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1252">approval</a></span>, all selected combinations of batch, strength, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> size, and fill, among other things, should also be <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tested</a></span> at 12 months or at the last time point prior to submission. in addition, data from at <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4598">least</a></span> three time points, including initial, 
should be available for each selected combination through the first 12 months of the study. for matrixing at an accelerated or intermediate <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition, care should be taken to ensure <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> occurs at a minimum of three time points, 
including initial and final, for each selected combination of factors. when a matrix on design factors is applied, if one strength or <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> size and/or 
fill is no longer intended for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/13"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1786">marketing</a></span></a></span>, stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> of that strength or <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> size and/or fill can be continued to support the other strengths or <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> sizes and/or fills in the design. 2.4.3 design examples examples of matrixing designs on time points for a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> in two strengths (s1 and s2) are shown in table 2. the terms ﬁone-half reductionﬂ and ﬁone-third reductionﬂ refer to the reduction strategy initially applied to the full study design. for example, a ﬁone-half reductionﬂ initially eliminates one in every two time points from the full 
study design and a ﬁone-third reductionﬂ initially removes one in every three. in the examples shown in table 2, the reductions are less than one-half and one-third due 
to the inclusion of full <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> of all factor combinations at some time points as bracketing and matrixing designs for stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span>  discussed in <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3803">section</a></span> 2.4.2. these examples include full <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> at the initial, final, and 12-month time points. the ultimate reduction is therefore less than one-half 
(24/48) or one-third (16/48), and is actually 15/48 or 10/48, respectively. table 2:   examples of matrixing designs on time points for a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> withtwo strengths ﬁone-half reductionﬂ time point (months) 0 3 6 9 12 18 24 36 batch 1 t t  t t  t t batch 2 t t  t t t  t s1 batch 3 t  t  t t  t batch 1 t  t  t  t t batch 2 t t  t t t  t   s   t   r   e   n   g   t   h s2 batch 3 t  t  t  t t key: t = <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/623">sample</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tested</a></span>   ﬁone-third reductionﬂ time point (months) 0 3 6 9 12 18 24 36 batch 1 t  t   t  t   t t batch 2 t t t  t t  t s1 batch 3 t  t t t t t t batch 1 t  t t t t t t batch 2 t t  t t  t t   s   t   r   e   n   g   t   h s2 batch 3 t t t  t t  t key: t = <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/623">sample</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tested</a></span>   additional examples of matrixing designs for a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> with three strengths and three <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> sizes are given in tables 3a and 3b. table 3a shows a design with 
matrixing on time points only and table 3b depicts a design with matrixing on time points and factors. in table 3a, all combinations of batch, strength, and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> size are <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tested</a></span>, while in table 3b, certain combinations of batch, strength and 
<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> size are not <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tested</a></span>.  5 bracketing and matrixing designs for stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span>  6 tables 3a and 3b: examples of matrixing designs for a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> with three   strengths and three <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> sizes 3a  matrixing on time points  strength            s1            s2            s3 <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> size a b c a b c a b c batch 1 t1 t2 t3 t2 t3 t1 t3 t1 t2 batch 2 t2 t3 t1 t3 t1 t2 t1 t2 t3 batch 3 t3 t1 t2 t1 t2 t3 t2 t3 t1  3b matrixing on time points and factors strength            s1            s2            s3 <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> size a b c a b c a b c batch 1 t1 t2  t2  t1  t1 t2 batch 2  t3 t1 t3 t1  t1  t3 batch 3 t3  t2  t2 t3 t2 t3   key: time-point (months) 0 3 6 9 12 18 24 36 t1 t  t t t t t t t2 t t  t t  t t t3 t t t  t t  t   s1, s2, and s3 are different strengths.  a, b, and c are different <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> sizes. t = <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/623">sample</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tested</a></span> 2.4.4 applicability and degree of reduction the following, although not an exhaustive list, should be considered when a matrixing design is contemplated:   knowledge of data variability   expected stability of the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span>  availability of supporting data   stability differences in the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> within a factor or among factors and/or   number of factor combinations in the study in general, a matrixing design is applicable if the supporting data indicate 
predictable <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> stability. matrixing is appropriate when the supporting data 
exhibit only small variability. however, where the supporting data exhibit moderate bracketing and matrixing designs for stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span>  variability, a matrixing design should be statistically justified. if the supportive data show large variability, a matrixing design should not be applied.  a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4256">statistical</a></span> justification could be based on an evaluation of the proposed matrixing design with respect to its power to detect differences among factors in the degradation rates or its precision in shelf life estimation. if a matrixing design is considered applicable, the degree of reduction that can be made from a full design <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5390">depends</a></span> on the number of factor combinations being evaluated. the more factors <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2944">associated</a></span> with a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> and the more levels in each 
factor, the larger the degree of reduction that can be considered. however, any reduced design should have the ability to adequately predict the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> shelf life. 2.4.5 potential risk  due to the reduced amount of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6030">data collected</a></span>, a matrixing design on factors other 
than time points generally has less precision in shelf life estimation and yields a 
shorter shelf life than the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/242">corresponding</a></span> full design. in addition, such a matrixing 
design may have insufficient power to detect certain main or <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6908">interaction</a></span> effects, thus <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2428">leading</a></span> to incorrect pooling of data from different design factors during shelf life 
estimation. if there is an excessive reduction in the number of factor combinations <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tested</a></span> and data from the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tested</a></span> factor combinations cannot be pooled to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/871">establish</a></span> a single shelf life, it may be impossible to estimate the shelf lives for the missing 
factor combinations.  a study design that matrixes on time points only would often have similar ability to that of a full design to detect differences in rates of change among factors and to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/871">establish</a></span> a reliable shelf life. this feature exists because linearity is assumed and 
because full <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> of all factor combinations would still be performed at both the initial time point and the last time point prior to submission. 2.5 data evaluation stability data from studies in a reduced design should be treated in the same 
<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5281">manner</a></span> as data from full design studies.  7 </body><html>